WO2006044439A3 - Methods of identifying metastatic potential in cancer - Google Patents

Methods of identifying metastatic potential in cancer Download PDF

Info

Publication number
WO2006044439A3
WO2006044439A3 PCT/US2005/036626 US2005036626W WO2006044439A3 WO 2006044439 A3 WO2006044439 A3 WO 2006044439A3 US 2005036626 W US2005036626 W US 2005036626W WO 2006044439 A3 WO2006044439 A3 WO 2006044439A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
metastatic potential
identifying metastatic
protein
Prior art date
Application number
PCT/US2005/036626
Other languages
French (fr)
Other versions
WO2006044439A2 (en
Inventor
Doina M Racila
Emilian V Racila
George J Weiner
Original Assignee
Univ Iowa Res Found
Doina M Racila
Emilian V Racila
George J Weiner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found, Doina M Racila, Emilian V Racila, George J Weiner filed Critical Univ Iowa Res Found
Publication of WO2006044439A2 publication Critical patent/WO2006044439A2/en
Publication of WO2006044439A3 publication Critical patent/WO2006044439A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention encompasses methods for predicting metastasis in cancer by assessing the structure of the complement protein ClqA. The methods may encompass examining either protein or nucleic acids, and may further include making treatment decisions based on the predictive methods.
PCT/US2005/036626 2004-10-19 2005-10-11 Methods of identifying metastatic potential in cancer WO2006044439A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62015704P 2004-10-19 2004-10-19
US60/620,157 2004-10-19

Publications (2)

Publication Number Publication Date
WO2006044439A2 WO2006044439A2 (en) 2006-04-27
WO2006044439A3 true WO2006044439A3 (en) 2007-08-02

Family

ID=36203478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/036626 WO2006044439A2 (en) 2004-10-19 2005-10-11 Methods of identifying metastatic potential in cancer

Country Status (1)

Country Link
WO (1) WO2006044439A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2797845C1 (en) * 2023-02-06 2023-06-08 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Method of predicting hematogenous metastasis of colon cancer after combined treatment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2315858A2 (en) * 2008-07-08 2011-05-04 Source Precision Medicine, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
CN106978477A (en) * 2016-08-17 2017-07-25 上海易瑞生物科技有限公司 A kind of Susceptibility for Cervical Cancer detection and genotyping kit and its application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CUQUERELLA S.M.: "Levels of Complement and Its Components in the Serum of Patients with Breast Cancer", vol. 12, no. 4, 1989, pages 170 - 176 *
RACILA D.M. ET AL.: "Homozygous Single Nucleotide Polymorphism of the Complement C1qA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus", LUPUS, vol. 12, 2003, pages 124 - 132 *
TAKADA K. ET AL.: "Complement Components, Whole Complement Activity, and Circulating Immune Complexes in Neoplastic Diseases", GAN NO RINSHO (JAPAN J. CANCER CLINICS), vol. 29, no. 4, April 1983 (1983-04-01), pages 293 - 296 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2797845C1 (en) * 2023-02-06 2023-06-08 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Method of predicting hematogenous metastasis of colon cancer after combined treatment

Also Published As

Publication number Publication date
WO2006044439A2 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
EP2154245A3 (en) Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
WO2007070280A3 (en) Use of deletion polymorphisms to predict, prevent, and manage histoincompatibility
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2009036427A3 (en) Prostate cancer biomarkers
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2008036691A3 (en) Biomarkers for prostate cancer and methods using the same
WO2005040396A3 (en) qRT-PCR ASSAY SYSTEM FOR GENE EXPRESSION PROFILING
EP2392678A3 (en) Prognosis prediction for colorectal cancer
WO2004044218A3 (en) Methods and materials for examining pathways associated with glioblastoma progression
WO2007035651A3 (en) Systemic lupus erythematosus diagnostic assay
ATE513216T1 (en) USE OF THE PROTEIN SATB2 AS A PROGNOSTIC MARKER FOR COLORECTAL CARCINOMA
WO2007103146A3 (en) Truncated proteins as cancer markers
WO2005094263A3 (en) Methods of determining the prognosis and treatment of subjects with colon cancer
WO2004053497A3 (en) Method for predicting the response to her2-directed therapy
WO2006110748A3 (en) Response gene to complement 32 (rgc-32) in disease
WO2005076939A3 (en) Assay and method for diagnosing and treating alzheimer’s disease
WO2002061144A8 (en) Brain tumor diagnosis and outcome prediction
WO2007112350A3 (en) Method of assessing the metastatic status of a primary tumor
WO2006074392A3 (en) Cancer prognostic, diagnostic and treatment methods
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
WO2006012356A3 (en) Methods for determining risk of developing regular smoking behavior
WO2006096697A3 (en) Methods for determining the bivalency of protein and antibody therapeutics
WO2005026392A3 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2005107803A3 (en) Methods of determining the prognosis and treatment of subjects with lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815605

Country of ref document: EP

Kind code of ref document: A2